Latent Hit Identification in Primary Screening Data with Compound Set Enrichment
Thibault Varin, PostDoctoral Fellow, Novartis, Speaking at Medchem Europe 2011.
Date Posted: Thursday, December 01, 2011
Novartis Launches 'Novartis Access' Novartis portfolio to be offered to governments and non-governmental organizations in low- and low-middle-income countries for USD 1 per treatment, per month. Friday, September 25, 2015Novartis, Amgen Partner The companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer's Disease (AD); Novartis' oral therapy CNP520 will be the lead molecule. Friday, September 04, 2015EU Approves Novartis's laBCC Therapy Novartis has announced that the European Commission has approved Odomzo® 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to curative surgery or radiation therapy. Monday, August 24, 2015